Research programme: proteolytic bacterial enzymes - Hansa Medical

Drug Profile

Research programme: proteolytic bacterial enzymes - Hansa Medical

Alternative Names: Endoglycosidase of Streptococcus pyogenes; EndoS; NiceR; Second generation IdeS; Second generation Ig-G-degrading enzyme of Streptococcus pyogenes

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hansa Medical AB
  • Class Anti-inflammatories; Bacterial proteins; Enzymes; Immunotherapies
  • Mechanism of Action Immunoglobulin modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Transplant rejection
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 02 Feb 2018 Preclinical development in Autoimmune disorders is still underway in Sweden
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Sweden (Parenteral)
  • 10 Apr 2015 Early research in Transplant rejection (Prevention) in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top